
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT
- About


ResMed Inc (RMD)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: RMD (1-star) has a low Upturn Star Rating. Not recommended to BUY.
1 Year Target Price $291.86
1 Year Target Price $291.86
8 | Strong Buy |
4 | Buy |
6 | Hold |
0 | Sell |
1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -23% | Avg. Invested days 35 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 40.32B USD | Price to earnings Ratio 28.99 | 1Y Target Price 291.86 |
Price to earnings Ratio 28.99 | 1Y Target Price 291.86 | ||
Volume (30-day avg) 19 | Beta 0.77 | 52 Weeks Range 199.07 - 293.81 | Updated Date 08/29/2025 |
52 Weeks Range 199.07 - 293.81 | Updated Date 08/29/2025 | ||
Dividends yield (FY) 0.75% | Basic EPS (TTM) 9.5 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-07-31 | When - | Estimate 2.48 | Actual 2.55 |
Profitability
Profit Margin 27.22% | Operating Margin (TTM) 33.87% |
Management Effectiveness
Return on Assets (TTM) 14.02% | Return on Equity (TTM) 25.86% |
Valuation
Trailing PE 28.99 | Forward PE 26.39 | Enterprise Value 39962081363 | Price to Sales(TTM) 7.83 |
Enterprise Value 39962081363 | Price to Sales(TTM) 7.83 | ||
Enterprise Value to Revenue 7.95 | Enterprise Value to EBITDA 21.28 | Shares Outstanding 146415008 | Shares Floating 145480712 |
Shares Outstanding 146415008 | Shares Floating 145480712 | ||
Percent Insiders 0.8 | Percent Institutions 64.76 |
Upturn AI SWOT
ResMed Inc

Company Overview
History and Background
ResMed Inc. was founded in 1989 by Peter Farrell, who spun it out of Baxter Healthcare. It focuses on developing, manufacturing, distributing, and marketing medical devices and cloud-based software solutions that diagnose, treat, and manage respiratory disorders, including sleep apnea, COPD, and other chronic diseases.
Core Business Areas
- Sleep and Respiratory Care: ResMed designs, manufactures, and distributes a comprehensive range of CPAP (continuous positive airway pressure) and APAP (automatic positive airway pressure) devices, masks, and related accessories for the treatment of sleep apnea. They also offer diagnostic equipment, ventilation devices, and cloud-based patient monitoring systems. Key revenue generator.
- Software as a Service (SaaS): ResMed provides cloud-based software solutions for managing patient data, improving adherence to therapy, and enhancing clinical outcomes. This includes platforms like Brightree and Propeller Health, offering solutions for home medical equipment (HME) providers and pharmaceutical companies managing respiratory diseases. Recurring revenue stream.
Leadership and Structure
ResMed is led by CEO Mick Farrell. The company operates with a global structure, with headquarters in San Diego, California, and regional offices worldwide. The organizational structure emphasizes innovation, product development, and customer support.
Top Products and Market Share
Key Offerings
- AirSense 10/11 Series: ResMed's AirSense 10 and 11 series are their flagship CPAP devices, known for their user-friendly design and advanced features. These devices treat sleep apnea, provide real time patient feedback, and monitor usage. Competitors include Philips Respironics (now recalling devices).
- AirFit/AirTouch Mask Series: ResMed's AirFit and AirTouch mask series offer a variety of mask options designed for comfort and effective therapy. The AirFit F20 and AirTouch F20 are popular full-face masks, while the AirFit N20 and P10 are nasal and nasal pillow masks, respectively. Competitors include Fisher & Paykel Healthcare.
- Brightree: Brightree is a cloud-based software platform for HME providers, offering billing, inventory management, and patient engagement solutions. This allows providers to work more efficiently and stay updated on patient progression with real-time metrics. Competitors include various HME billing software providers.
- Astral Series: ResMed's Astral Series is a portable ventilator that provides invasive and non-invasive respiratory support for patients with chronic respiratory conditions. Competitors include Hamilton Medical and Dru00e4ger.
Market Dynamics
Industry Overview
The sleep apnea and respiratory care market is driven by the increasing prevalence of sleep apnea, COPD, and other respiratory disorders, as well as an aging population and rising awareness of treatment options. The market is competitive and regulated by various government health administrations.
Positioning
ResMed is a global leader in the sleep apnea and respiratory care market, known for its innovative products, strong brand reputation, and extensive distribution network. Their competitive advantages include a focus on technological innovation, cloud-based solutions, and patient-centric design.
Total Addressable Market (TAM)
The global sleep apnea devices market is projected to reach around $12 billion to $15 billion. The wider respiratory devices market is much larger. ResMed Inc. is a significant player within these markets and is positioned to take advantage of increased awareness and adoption of treatment. SaaS solutions also increase TAM potential.
Upturn SWOT Analysis
Strengths
- Strong brand recognition
- Extensive product portfolio
- Global distribution network
- Innovation in cloud-based solutions
- Experienced management team
Weaknesses
- Dependence on reimbursement policies
- Exposure to regulatory risks
- Supply chain vulnerabilities
- Recall of Philips Respironics provides opportunity but also highlights potential issues.
Opportunities
- Expanding into emerging markets
- Developing new therapies and diagnostic tools
- Acquiring complementary businesses
- Leveraging cloud-based solutions for remote patient monitoring
Threats
- Increased competition
- Technological obsolescence
- Changes in reimbursement policies
- Economic downturns
Competitors and Market Share
Key Competitors
- Fisher & Paykel Healthcare (FPH.NZ)
- Philips (PHG)
- Invacare (IVC)
Competitive Landscape
ResMed holds a leading position due to superior technologies, quality products, established distribution network and services. Philips Respironics, although experiencing recalls, remains a formidable competitor. Fisher & Paykel Healthcare focuses on product comfort and also has a strong presence.
Major Acquisitions
Propeller Health
- Year: 2019
- Acquisition Price (USD millions): 225
- Strategic Rationale: To expand ResMed's digital health offerings and provide connected solutions for respiratory care.
Medistar
- Year: 2018
- Acquisition Price (USD millions):
- Strategic Rationale: Medistar is a U.S.-based healthcare software company focusing on cloud-based platforms to manage senior living. This acquisition broadens ResMed's capabilities in remote patient monitoring and digital health services for aging populations, enhancing chronic disease management.
Growth Trajectory and Initiatives
Historical Growth: ResMed has demonstrated consistent growth over the past decade, driven by increasing demand for sleep apnea treatment and expansion into new markets. Their SaaS solutions have contributed to recurring revenue growth.
Future Projections: Analysts project continued growth for ResMed, driven by increasing demand for sleep apnea treatment, the aging population, and the expansion of their SaaS business. Innovation in digital health solutions is also expected to drive future growth.
Recent Initiatives: Recent initiatives include strategic acquisitions, partnerships to expand product offerings, and investments in digital health and remote patient monitoring technologies.
Summary
ResMed is a leading player in sleep apnea and respiratory care, holding a strong market position due to its innovative products and extensive distribution network. They have consistently improved the companyu2019s financials due to solid products and a shift to subscription based services. However, the company must watch out for increased competition and regulatory changes. Diversification into SaaS is a successful strategy for future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- ResMed Investor Relations
- Analyst Reports
- Industry Publications
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market data is subject to change. Consult a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ResMed Inc
Exchange NYSE | Headquaters San Diego, CA, United States | ||
IPO Launch date 1995-06-02 | CEO & Chairman Mr. Michael J. Farrell BE, MBA, SM | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 10600 | Website https://www.resmed.co.in |
Full time employees 10600 | Website https://www.resmed.co.in |
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.